LIVIVO - Search results -

Search results

Result 1 - 10 of total 65

Search options

Book: Management of high grade bladder cancer

Balar, Arjun V.

a multidisciplinary approach

(Urologic clinics of North America ; 42,2)

2015

Author's details	ed.: Arjun V. Balar
Series title	Urologic clinics of North America ; 42,2 The urologic clinics of North America
Collection	The urologic clinics of North America
Language	English
Size	XII S., S. 148 - 268 : Ill., graph. Darst.
Publisher	Elsevier
Publishing place	Philadelphia, Pa. u.a.
Publishing country	United States
Document type	Book
HBZ-ID	HT018665186
ISBN	978-0-323-37623-5 ; 0-323-37623-1
Database	Catalogue ZB MED Medicine, Health

In stock of ZB MED Cologne/Königswinter

Shelf mark	Loan status	Location
Se 269 -42,2-	verfügbar in Königswinter	Königswinter

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article: Recent Clinical Trials Explore Immunotherapies for Urothelial Carcinoma.

Balar, Arjun V

Oncology (Williston Park, N.Y.)

2019 Volume 33, Issue 4, Page(s) 132–136

MeSH term(s)	Antibodies, Monoclonal, Humanized/therapeutic use ; Antineoplastic Agents, Immunological/therapeutic use ; B7-H1 Antigen/antagonists & inhibitors ; Carcinoma, Transitional Cell/drug therapy ; Carcinoma, Transitional Cell/pathology ; Carcinoma, Transitional Cell/surgery ; Chemotherapy, Adjuvant ; Cystectomy/methods ; Drug Therapy, Combination/methods ; Humans ; Immunotherapy ; Interleukin-2/analogs & derivatives ; Interleukin-2/therapeutic use ; Neoplasm Invasiveness ; Neoplasm Staging ; Nivolumab/therapeutic use ; Polyethylene Glycols/therapeutic use ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Urinary Bladder Neoplasms/drug therapy ; Urinary Bladder Neoplasms/pathology ; Urinary Bladder Neoplasms/surgery
Chemical Substances	Antibodies, Monoclonal, Humanized ; Antineoplastic Agents, Immunological ; B7-H1 Antigen ; Interleukin-2 ; Programmed Cell Death 1 Receptor ; Nivolumab (31YO63LBSN) ; Polyethylene Glycols (3WJQ0SDW1A) ; atezolizumab (52CMI0WC3Y) ; bempegaldesleukin (BNO1JG5MZC) ; pembrolizumab (DPT0O3T46P)
Language	English
Publishing date	2019-04-15
Publishing country	United States
Document type	Journal Article
ZDB-ID	1067950-9
ISSN	0890-9091
ISSN	0890-9091
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3168: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 372: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Erdheim-Chester Disease with BRAF V600E Mutation and a Concomitant Myeloid Malignancy Sharing NRAS and IDH2 Mutations.

Prabhakaran, Nitya / Jour, George / Balar, Arjun / Ward, Nicholas

Acta haematologica

2023 Volume 146, Issue 3, Page(s) 245–251

Abstract: Erdheim-Chester disease (ECD) is a rare clonal histiocytic process that is characterized by a foamy (xanthomatous) proliferation often associated with Touton giant cells. The diagnosis is often challenging and not exclusively a histologic diagnosis, as ... ...

Abstract	Erdheim-Chester disease (ECD) is a rare clonal histiocytic process that is characterized by a foamy (xanthomatous) proliferation often associated with Touton giant cells. The diagnosis is often challenging and not exclusively a histologic diagnosis, as it requires correlation with unique clinical, radiographic, and recently described molecular findings. Activating mutations involving the MAPK pathway including BRAF, ARAF, N/KRAS, and MEK are recurrent in the disease. However, it is increasingly being described that mutations associated with clonal hematopoiesis are also found in bone marrow specimens of patients with ECD, as well as higher frequency of overt concomitant myeloid malignancy including acute myeloid leukemia, myeloproliferative neoplasms, myelodysplastic syndromes, and mixed myeloproliferative neoplasms/myelodysplastic syndromes. Herein, we report a unique case of a patient presenting with BRAFV600E-positive ECD with peripheral blood findings consistent with a concurrent myeloid malignancy featuring co-occurrence of NRAS and IDH2 mutations.
MeSH term(s)	Humans ; Erdheim-Chester Disease/diagnosis ; Erdheim-Chester Disease/genetics ; Erdheim-Chester Disease/complications ; Proto-Oncogene Proteins B-raf/genetics ; Mutation ; Myeloproliferative Disorders/diagnosis ; Myeloproliferative Disorders/genetics ; Myeloproliferative Disorders/complications ; Neoplasms/complications ; Myelodysplastic Syndromes/complications ; Membrane Proteins/genetics ; GTP Phosphohydrolases/genetics
Chemical Substances	Proto-Oncogene Proteins B-raf (EC 2.7.11.1) ; BRAF protein, human (EC 2.7.11.1) ; NRAS protein, human (EC 3.6.1.-) ; Membrane Proteins ; GTP Phosphohydrolases (EC 3.6.1.-)
Language	English
Publishing date	2023-02-08
Publishing country	Switzerland
Document type	Case Reports
ZDB-ID	80008-9
ISSN	1421-9662 ; 0001-5792
ISSN (online)	1421-9662
ISSN	0001-5792
DOI	10.1159/000528550
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ud II Zs.145: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Immune Checkpoint Blockade in Metastatic Urothelial Cancer.

Balar, Arjun Vasant

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

2017 Volume 35, Issue 19, Page(s) 2109–2112

Abstract: The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a ... ...

Abstract	The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice. A 62-year-old man with a 45 pack per year tobacco-smoking history presented with painless gross hematuria in the fall of 2015 and was ultimately diagnosed with muscle-invasive urothelial bladder cancer. He received four cycles of cisplatin-based neoadjuvant chemotherapy followed by radical cystectomy with pelvic lymph node dissection, which disclosed residual high-grade muscle-invasive urothelial cancer extending to the perivesical fat and involving two of 20 pelvic lymph nodes (pT3N2). Six months later, surveillance imaging identified new retroperitoneal lymphadenopathy and a large right pelvic mass with possible rectal wall invasion consistent with locally recurrent and metastatic urothelial cancer. Although feeling generally well, he reported having had progressive constipation, pelvic pressure, and narrow-caliber stools for 2 months. He was seen in consultation for management of recurrent bladder cancer.
MeSH term(s)	B7-H1 Antigen/antagonists & inhibitors ; B7-H1 Antigen/immunology ; Chemotherapy, Adjuvant ; Humans ; Male ; Middle Aged ; Neoadjuvant Therapy ; Neoplasm Invasiveness ; Urinary Bladder Neoplasms/drug therapy ; Urinary Bladder Neoplasms/pathology ; Urinary Bladder Neoplasms/surgery ; Urologic Neoplasms/drug therapy ; Urologic Neoplasms/immunology ; Urologic Neoplasms/pathology
Chemical Substances	B7-H1 Antigen ; CD274 protein, human
Language	English
Publishing date	2017-07-01
Publishing country	United States
Document type	Case Reports ; Journal Article
ZDB-ID	604914-x
ISSN	1527-7755 ; 0732-183X
ISSN (online)	1527-7755
ISSN	0732-183X
DOI	10.1200/JCO.2017.72.8444
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1847: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 650: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Pembrolizumab monotherapy for high-risk, non-muscle invasive bladder cancer - Authors' reply.

Balar, Arjun V / Kamat, Ashish M / de Wit, Ronald

The Lancet. Oncology

2021 Volume 22, Issue 9, Page(s) e380

MeSH term(s)	Antibodies, Monoclonal, Humanized/adverse effects ; Antineoplastic Agents, Immunological/adverse effects ; Humans ; Urinary Bladder Neoplasms/drug therapy
Chemical Substances	Antibodies, Monoclonal, Humanized ; Antineoplastic Agents, Immunological ; pembrolizumab (DPT0O3T46P)
Language	English
Publishing date	2021-09-03
Publishing country	England
Document type	Letter ; Comment
ZDB-ID	2049730-1
ISSN	1474-5488 ; 1470-2045
ISSN (online)	1474-5488
ISSN	1470-2045
DOI	10.1016/S1470-2045(21)00478-2
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5696: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 460: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Immune Checkpoint Inhibitors for Genitourinary Cancers: Treatment Indications, Investigational Approaches and Biomarkers.

Labadie, Brian W / Balar, Arjun V / Luke, Jason J

Cancers

2021 Volume 13, Issue 21

Abstract: Cancers of the genitourinary (GU) tract are common malignancies in both men and women and are a major source of morbidity and mortality. Immune checkpoint inhibitors (ICI) targeting CTLA-4, PD-1 or PD-L1 have provided clinical benefit, particularly in ... ...

Abstract	Cancers of the genitourinary (GU) tract are common malignancies in both men and women and are a major source of morbidity and mortality. Immune checkpoint inhibitors (ICI) targeting CTLA-4, PD-1 or PD-L1 have provided clinical benefit, particularly in renal cell and urothelial carcinoma, and have been incorporated into standard of care treatment in both localized and metastatic settings. However, a large fraction of patients do not derive benefit. Identification of patient and tumor-derived factors which associate with response have led to insights into mechanisms of response and resistance to ICI. Herein, we review current approvals and clinical development of ICI in GU malignancies and discuss exploratory biomarkers which aid in personalized treatment selection.
Language	English
Publishing date	2021-10-28
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2527080-1
ISSN	2072-6694
ISSN	2072-6694
DOI	10.3390/cancers13215415
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Current Status and Future Direction of Immunotherapy in Urothelial Carcinoma.

Lattanzi, Michael / Balar, Arjun V

Current oncology reports

2019 Volume 21, Issue 3, Page(s) 24

Abstract: Purpose of review: Since 2016, five new programmed cell death protein 1/ligand 1 (PD-1/L1) checkpoint inhibitors have been approved for metastatic urothelial carcinoma. This review will summarize the data supporting the widespread use of these agents ... ...

Abstract	Purpose of review: Since 2016, five new programmed cell death protein 1/ligand 1 (PD-1/L1) checkpoint inhibitors have been approved for metastatic urothelial carcinoma. This review will summarize the data supporting the widespread use of these agents and highlight areas of ongoing clinical development. Recent findings: PD-1/L1 axis inhibition has demonstrated clear superiority to chemotherapy for the treatment of metastatic urothelial cancer in the second-line setting. A multitude of ongoing studies are investigating the feasibility and efficacy of incorporating established and novel immunotherapies into earlier lines of therapy, including non-metastatic muscle-invasive bladder cancer and even non-muscle-invasive disease. Early-phase clinical trials have begun to explore the safety and activity of novel immune-oncology combinations across a range of clinical settings. Immunotherapy has a clearly defined role in the treatment of metastatic urothelial cancer both in the platinum-refractory setting and in the first-line cisplatin-ineligible setting. Ongoing clinical trials will dictate how to best incorporate immunotherapy into earlier lines of therapy and define the safety and activity of novel immunotherapy agents and combinations.
MeSH term(s)	Animals ; Antineoplastic Agents, Immunological/therapeutic use ; Humans ; Immunologic Factors/immunology ; Immunologic Factors/therapeutic use ; Immunotherapy/methods ; Urinary Bladder Neoplasms/drug therapy ; Urinary Bladder Neoplasms/immunology ; Urinary Bladder Neoplasms/pathology
Chemical Substances	Antineoplastic Agents, Immunological ; Immunologic Factors
Language	English
Publishing date	2019-02-26
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	2057359-5
ISSN	1534-6269 ; 1523-3790
ISSN (online)	1534-6269
ISSN	1523-3790
DOI	10.1007/s11912-019-0775-5
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5521: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: PD-1/PD-L1 Combinations in Advanced Urothelial Cancer: Rationale and Current Clinical Trials.

Hsu, Miles M / Balar, Arjun V

Clinical genitourinary cancer

2019 Volume 17, Issue 3, Page(s) e618–e626

Abstract: Chemotherapy is no longer the only viable option for patients with locally advanced or metastatic urothelial carcinoma. Immunotherapy, as checkpoint inhibition, has received United States Food and Drug Administration approval in the preceding several ... ...

Abstract	Chemotherapy is no longer the only viable option for patients with locally advanced or metastatic urothelial carcinoma. Immunotherapy, as checkpoint inhibition, has received United States Food and Drug Administration approval in the preceding several years, both in the second-line and first-line for cisplatin-ineligible patients. Those who respond often do so durably; however, response rates in the first line are 23% to 24%, and are lower in the second line. With a focus on urothelial carcinoma, this review discusses the tumor microenvironment and its negative influence on anti-tumor immunity, as well as measures to counteract immune suppression or evasion. The review then describes a range of current clinical trials implementing these measures in the form of programmed death-combination therapy, specifically in advanced bladder and urothelial cancers.
MeSH term(s)	Antineoplastic Agents, Immunological/pharmacology ; Antineoplastic Agents, Immunological/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; B7-H1 Antigen/antagonists & inhibitors ; Carcinoma, Transitional Cell/drug therapy ; Carcinoma, Transitional Cell/immunology ; Clinical Trials as Topic ; Humans ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Survival Analysis ; Treatment Outcome ; Tumor Microenvironment/drug effects ; Urologic Neoplasms/drug therapy ; Urologic Neoplasms/immunology
Chemical Substances	Antineoplastic Agents, Immunological ; B7-H1 Antigen ; CD274 protein, human ; PDCD1 protein, human ; Programmed Cell Death 1 Receptor
Language	English
Publishing date	2019-03-29
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Review
ZDB-ID	2225121-2
ISSN	1938-0682 ; 1558-7673
ISSN (online)	1938-0682
ISSN	1558-7673
DOI	10.1016/j.clgc.2019.03.009
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6168: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The impact of taxanes on the management of genitourinary cancers.

Balar, Arjun V

Anti-cancer drugs

2014 Volume 25, Issue 5, Page(s) 555–560

Abstract: Taxanes have had a profound impact on the management of genitourinary tumors. In the perioperative and metastatic setting in bladder cancer, taxanes such as paclitaxel have an established role in combination chemotherapy strategies to improve survival. ... ...

Abstract	Taxanes have had a profound impact on the management of genitourinary tumors. In the perioperative and metastatic setting in bladder cancer, taxanes such as paclitaxel have an established role in combination chemotherapy strategies to improve survival. In metastatic prostate cancer, docetaxel was the only treatment, until recently, shown to improve survival after the development of castration resistance. More recently, cabazitaxel, a synthetic taxane derivative, is an effective option after docetaxel failure. In advanced testicular cancer, taxanes play an important role in the management of relapsed disease with the ability to still achieve cure. This chapter will focus on the development and current role of taxanes in the treatment of genitourinary cancers including bladder, prostate, and testis cancers as well as the status of novel agents currently under investigation.
MeSH term(s)	Antineoplastic Agents, Phytogenic/therapeutic use ; Humans ; Male ; Prostatic Neoplasms/drug therapy ; Taxoids/therapeutic use ; Testicular Neoplasms/drug therapy ; Urinary Bladder Neoplasms/drug therapy
Chemical Substances	Antineoplastic Agents, Phytogenic ; Taxoids
Language	English
Publishing date	2014-05
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	1065301-6
ISSN	1473-5741 ; 0959-4973
ISSN (online)	1473-5741
ISSN	0959-4973
DOI	10.1097/CAD.0000000000000088
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 3125: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Atezolizumab in invasive and metastatic urothelial carcinoma.

Crist, Michael / Balar, Arjun

Expert review of clinical pharmacology

2017 , Page(s) 1–7

Abstract: Introduction: Until recently, there has been little advancement in the management of invasive and metastatic urothelial cancer in over 30 years, and outcomes with cisplatin-based chemotherapy remain unchanged. Inhibitors targeting PD-1 signaling on ... ...

Abstract	Introduction: Until recently, there has been little advancement in the management of invasive and metastatic urothelial cancer in over 30 years, and outcomes with cisplatin-based chemotherapy remain unchanged. Inhibitors targeting PD-1 signaling on cytotoxic T-cells have revolutionized bladder cancer therapy leading to durable responses. Atezolizumab is an engineered humanized anti-PD-L1 monoclonal antibody that inhibits PD-L1 binding to PD-1 and B7.1, enhancing immune-mediated tumor killing and is currently approved as second-line treatment after failure of platinum-based chemotherapy as well as first-line in cisplatin-ineligible patients. Areas covered: This article summarizes all reported phase I, II and III clinical trials that assessed the safety and efficacy of atezolizumab in the treatment of locally advanced and metastatic urothelial carcinoma. Expert commentary: Treatment with atezolizumab showed durable response and a toxicity profile that appears favorable to cytotoxic chemotherapy historically in the treatment of metastatic urothelial cancer among individuals who had progressed after prior platinum-based therapy and among those ineligible for treatment with first-line cisplatin. PD-L1 expression and tumor mutation load associate with response, however further research is needed to identify additional markers to improve prediction of response to atezolizumab.
Language	English
Publishing date	2017-10-30
Publishing country	England
Document type	Journal Article
ISSN	1751-2441
ISSN (online)	1751-2441
DOI	10.1080/17512433.2017.1389275
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED